<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01927406</url>
  </required_header>
  <id_info>
    <org_study_id>26654</org_study_id>
    <nct_id>NCT01927406</nct_id>
  </id_info>
  <brief_title>The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.</brief_title>
  <official_title>The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential secondary beneficial effect of
      prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients. This study aims
      to determine if PA would change the course of the orbitopathy in TED patients by altering the
      progression of the common features of TED, including fatty hypertrophy, proptosis, eyelid
      retraction and optic nerve compression. The eyes with thyroid eye disease and elevated
      intraocular pressure will be randomised to the PA treatment and the other eye will serve as a
      control eye and will be treated with Timolol.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding source unavailable
  </why_stopped>
  <start_date type="Anticipated">June 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in appearance of facial periorbital region at 6 months.</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hertel exophthalmometry at 3, 6, 9 and 12 months.</measure>
    <time_frame>Baseline and 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in intraocular pressure at 3, 6, 9 and 12 months.</measure>
    <time_frame>Baseline and 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in appearance of facial periorbital region at 3, 6, 9 and 12 months.</measure>
    <time_frame>Baseline and 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Thyroid Eye Disease</condition>
  <condition>Ocular Hypertension</condition>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Prostaglandin Analog vs Timolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, with thyroid eye disease and increased intraocular pressure in both eyes, prostaglandin analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one - randomised eye. Timolol 0.5% eye drop will be administered topically in second, control eye, two times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostaglandin Analog</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group, with thyroid eye disease and increased intraocular pressure in only one eye Prostaglandin Analog eyedrop (bimatoprost 0.01%, travoprost z 0.004%, tafluprost 0.0015% or latanoprost 0.005%) will be administered once a day, topically, into one, affected eye.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostaglandin Analog</intervention_name>
    <description>The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.</description>
    <arm_group_label>Prostaglandin Analog vs Timolol</arm_group_label>
    <arm_group_label>Prostaglandin Analog</arm_group_label>
    <other_name>Bimatoprost</other_name>
    <other_name>Travoprost Z</other_name>
    <other_name>Tafluprost</other_name>
    <other_name>Latanoprost</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol</intervention_name>
    <description>Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.</description>
    <arm_group_label>Prostaglandin Analog vs Timolol</arm_group_label>
    <other_name>Timolol maleate 0.5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild or moderate to severe thyroid eye disease in one or both eyes

          -  age &gt; 18 years

          -  informed consent

          -  intraocular pressure &gt; 21 mmHg or glaucoma suspect or glaucoma diagnosed in one or
             both eyes

          -  not on current prostaglandin analog intraocular pressure lowering therapy

        Exclusion Criteria:

          -  sight threatening thyroid eye disease

          -  children &lt; 18 years old

          -  patients that are not compliant with treatment or follow-up

          -  patients already on prostaglandin analog treatment

          -  patients that undergo cosmetic periocular procedures during the study will be excluded
             from further follow up

          -  patients that cannot tolerate prostaglandin analog treatment.

          -  patients with bilateral thyroid eye disease and elevated intraocular pressures that
             cannot tolerate treatment with timolol or an alternative intraocular pressure lowering
             medication such as trusopt, combigan, cosopt.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea L. Kossler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2013</study_first_submitted>
  <study_first_submitted_qc>August 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2013</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrea L Kossler</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Thyroid Eye Disease</keyword>
  <keyword>Graves' Disease</keyword>
  <keyword>Prostaglandin Analogues</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Bimatoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

